Navigation Links
Concerned Stockholders Launch Save Vermillion! Website: www.savevrml.com
Date:2/1/2013

PHILADELPHIA, Feb. 1, 2013 /PRNewswire/ -- George Bessenyei , Gregory V. Novak , and Robert S. Goggin (the "Group") today launched their website, www.savevrml.com, to provide all stockholders access to relevant information concerning Vermillion Inc.'s (the "Company" or "Vermillion") contested 2012 Annual Stockholder meeting (the "2012 Annual Meeting").

The road to forcing Vermillion's Board to schedule the annual meeting has been anything but easy, short, or smooth.  Almost a year ago, on February 15, 2012, the Group announced its intention to nominate Robert S. Goggin as Director Nominee for the 2012 Annual Meeting. After a series of dodge ball tactics by the Board and Gail Page , more recently, on January 9, 2013, Bessenyei filed a complaint in the Delaware Chancery Court ("Court"), asking the Court to order the Company to call and hold an annual meeting of stockholders at the earliest practicable date. This maneuver was necessary, given what the Group believes was management's stonewalling, to finally force the Company to abide by its own Bylaws, Delaware law and to avoid a NASDAQ delisting process, and call the 2012 meeting.  After the complaint was filed, the Company finally set the meeting date for March 21st, 2013.

In order to provide more information to stockholders, the Group today launched its website. Major topics include: 

  • Robert S. Goggin 's Five Point Turnaround Plan for Vermillion
  • Comprehensive analysis of OVA1 and its market potential
  • Biography of Group members
  • Timeline of events leading to the 2012 Annual Meeting
  • Compensation counter tracking the benefits provided to Vermillion Directors over the past several years, currently standing at a staggering $13,176,632
  • The Reverse Midas Touch: Chairman James S. Burns ' track record at public companies*

Visit our webpage today!

The Group's proxy statement (the "Group Proxy Statement"), filed on January 29, 2013, is available free of charge at www.sec.gov.  The Group Proxy Statement will first be sent or given to stockholders on or about February 6, 2013.  Stockholders are advised to read the Group Proxy Statement and the other documents relating to the Group's solicitation of proxies by members of the Group from stockholders of the Company for use at its 2012 Annual Meeting because they contain important information.

*( James S. Burns serves as Chairman of the Board at Vermillion; he is also a Director at Symmetry Medical, Inc. and Chief Executive Officer at AssureRx Health, Inc.)

Stockholders please contact Okapi Partners LLC
Patrick McHugh / Geoff Sorbello
(212) 297-0720

Concerned Vermillion Stockholders
T: 561-444-8180
Email: concerned_vrml@googlegroups.com


'/>"/>
SOURCE Concerned Vermillion Stockholders
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
2. Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
3. Generex Announces Date of Annual Stockholders Meeting
4. Amarantus BioScience Launches New Website
5. Touch Medical Media Splits From Touch Briefings, Launches a Series of Cutting Edge, Free to Access, Educational Resources and Signs an Updated Media Partnership With ECCO, The European CanCer Organisation Representing 60,000 Oncology Professionals
6. Find New Cancer Treatments at cureLauncher
7. New York Microscope Launches New Website http://www.NYscopes.com
8. MDA Launches Clinical Network to Speed Myotonic Dystrophy Research
9. DuPont Pioneer Launches Next Generation T Series Soybeans
10. MedZilla.com Launches New Site Design for 2013, Slick New Interface Impresses
11. Nerium Announcing Launch of New Blog Sites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
Breaking Biology News(10 mins):